OR WAIT null SECS
Lonza introduces new modular complex that offers flexibility and individually tailored solutions to biomanufacturing challenges.
Lonza has launched its new biomanufacturing complex, Ibex Solutions, a biological development and manufacturing concept that combines flexibility in facility build-out with tailored business models and leverages Lonza’s expertise and service network in Visp, Switzerland. Construction of the complex began in June 2017 and a formal groundbreaking ceremony is expected to take place in the second half of 2017.
Ibex biomanufacturing comprises a modular, technology-independent development and manufacturing complex capable of supporting activities across multiple technologies, including mammalian, microbial, cellular, or bio-conjugate. The complex is also capable of supporting activities ranging from late discovery to manufacture. This flexibility allows for freedom in facility design and implementation as well as the ability to respond rapidly to changing needs.
Responsiveness is further enhanced by the integration of the Ibex biomanufacturing complex into the Visp site. Ibex Solutions include flexible models that can match and adapt to individual expectations and forecasts. The availability of a modular complex can reduce time-to-market by 12 months or more, according to Lonza.
Lonza’s Pharma&Biotech COO, Marc Funk, stated in a company press release: “Lonza has been creating innovative manufacturing and production solutions for 120 years, and we are continuing to pioneer clinical and commercial manufacturing in multiple technologies all over the world. We have been working with our partners to understand what we can offer that will really change the game for them, and that’s why we have created Ibex.”